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Methicillin-resistant  Staphylococcus aureus (MRSA) 
bacteremia is often fatal. To determine predictors of risk 
for death, we conducted a retrospective cohort study. We 
examined 699 episodes of MRSA bacteremia involving 
603 patients admitted to an academic medical center in 
New York City during 2002–2007. Data came from chart 
reviews, hospital databases, and recultured frozen MRSA 
specimens. Among the 699 episodes, 55 were caused by 
vancomycin–intermediate resistant S. aureus strains, 55 by 
heteroresistant vancomycin-intermediate S. aureus strains, 
and 589 by non–vancomycin-resistant strains; 190 (31.5%) 
patients died. We used regression risk analysis to quantify 
the association between clinical correlates and death. We 
found that older age, residence in a nursing home, severe 
bacteremia, and organ impairment were independently 
associated with increased risk for death; consultation with 
an infectious disease specialist was associated with lower 
risk for death; and MRSA strain types were not associated 
with risk for death.
M
ethicillin-resistant Staphylococcus aureus (MRSA) 
is a worldwide concern; it colonizes and infects 
patients in the hospital and in the community (1). For the 
past 50 years in the United States, the standard therapy 
has been vancomycin. Recent vancomycin treatment 
failures have raised questions regarding optimal treatment 
(2). Although new antimicrobial drugs (e.g., linezolid, 
daptomycin, tigecycline) have been developed, none has 
been consistently superior to vancomycin for the treatment 
of MRSA (3,4), and MRSA resistance rapidly develops for 
many new drugs (5,6). Some studies have suggested MIC 
creep (increasing vancomycin MICs against MRSA over 
time), but others have not (7,8). In 2006, the upper limit 
of vancomycin susceptibility for S. aureus was redeﬁ  ned, 
lowered from 4 μg/mL to 2 μg/mL, ﬁ  rst by the Clinical 
and Laboratory Standards Institute and soon thereafter by 
the US Food and Drug Administration and the European 
Committee on Antimicrobial Susceptibility (9).
Vancomycin treatment failures for MRSA occur even 
when MICs are within the range considered susceptible, 
especially 1–2 μg/mL (10–13). Among high-risk bacteremic 
patients, Sakoulas et al. documented treatment failure rates 
of 44% when vancomycin MICs were <0.5 μg/mL and of 
90% when vancomycin MICs were 1–2 μg/mL (p = 0.01) 
(10). Hidayat et al. found that mortality rates were higher 
for patients infected with strains with higher vancomycin 
MICs (11)
Some apparently susceptible strains of MRSA might 
actually be heteroresistant  vancomycin-intermediate  S. 
aureus (hVISA) strains. That is, although the hVISA 
isolates seem to be susceptible to vancomycin according 
to conventional testing, the isolates contain subpopulations 
of colonies resistant to vancomycin. Testing for hVISA 
has not been standardized and is not routinely undertaken. 
hVISA strains are more common in strains with higher 
vancomycin MICs (14,15). hVISA might contribute to 
worse clinical outcomes, but this possibility has not been 
convincingly conﬁ  rmed by large studies.
To determine predictors of risk for death among patients 
with MRSA bacteremia, we conducted a retrospective study 
that compared demographic and clinical characteristics of 
adult patients with MRSA bacteremia. MRSA strains from 
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these patients were vancomycin susceptible, VISA, and 
hVISA. We analyzed a 5-year trend of vancomycin MICs 
among adult patients with MRSA bacteremia. We also 
analyzed the associations between host factors, organism 
factors, and death versus survival, and quantifed the 
marginal contribution of key factors to risk for death. 
Methods
Our retrospective study was conducted in New York, 
New York, USA, at Mount Sinai Medical Center, a 1,171-
bed tertiary-care academic center that serves a diverse 
ethnic and medical population. We studied 699 episodes 
of blood infection from 603 patients who had had MRSA 
bacteremia during 2002–2007. This study was approved by 
the institutional review board of the Mount Sinai School of 
Medicine.
Laboratory Specimens
At Mount Sinai Medical Center, MRSA organisms 
identiﬁ  ed from blood culture are routinely stored frozen 
at  −70°C. We retrieved frozen blood culture isolates 
(previously not thawed or subcultured) for all adult patients 
hospitalized with MRSA bacteremia from January 2002 
through May 2007. We excluded episodes of polymicrobial 
bacteremia if MRSA was isolated in a single blood culture 
bottle or if the patient received inappropriate empirical 
treatment for the co-pathogen. We included in our analysis 
the ﬁ  rst organism isolated from blood culture during any 
episode of MRSA bacteremia. 
A computerized data system identiﬁ  ed 748 eligible 
isolates, among which we were able to retrieve 699 
(93.4%). These isolates had originally been tested for 
drug susceptibility by use of an automated instrument, the 
Microscan (Siemens Healthcare, Sacramento, CA, USA); 
for all isolates, the vancomycin MICs were <2 μg/mL; 
during 2002–2007, we used the Positive Breakpoint Combo 
20 (Siemens Healthcare), which might not accurately 
detect VISA isolates (16). We sent some isolates—8 
(15%) VISA strains, 88 (15%) non-VISA strains, and 10 
VISA control strains (from the Network on Antimicrobial 
Resistance in Staphylococcus aureus, www.narsa.net)—to 
an outside laboratory for blinded testing by using the Vitek 
2 (bioMérieux, Durham, NC, USA) with the AST-GP-67 
card, and we sent 8 (15%) hVISA isolates to an outside 
laboratory for retesting by using time-killing proﬁ  les. No 
discrepancies were noted.
Retesting of isolates was performed with no access 
(blinded) to clinical data. Mueller-Hinton agar plates 
(study and control strains) were inoculated with 0.5 
McFarland inoculum (108 CFU/mL), and antimicrobial 
drug susceptibility to vancomycin was assessed by using 
Etest (AB Biodisk, Solna, Sweden), which has excellent 
sensitivity and speciﬁ  city for this purpose (17). Isolates for 
which vancomycin MICs were >1 μg/mL (95.1%) were 
tested for the presence of hVISA by using vancomycin and 
teicoplanin Etest strips (the Etest macromethod). In brief, 
study and control inocula equivalent to 2.0 McFarland 
turbidity standard were plated on brain–heart infusion and 
Mueller-Hinton agars and incubated at 35°C–37°C for 24 
and 48 hours, respectively. Isolates were interpreted as 
being hVISA strains when vancomycin and teicoplanin 
MICs were >8 μg/mL or teicoplanin-only MIC was >12 
μg/mL (16). Quality control testing was performed weekly 
by using American Type Culture Collection (Manassas, 
VA, USA) organisms 29213, 29212, 700698 (hVISA), 
and 700699 (VISA) per Clinical and Laboratory Standards 
Institute guidelines (9). Actual Etest values were used for 
MIC50 (the value below which 50% of MIC values for 
MRSA isolates tested fell), MIC90 (the value below which 
90% of MICs fell), and geometric mean MIC calculations.
Chart Review
We abstracted electronic and paper charts for each 
of the 603 patients corresponding to the 699 isolates; 
65 of these patients were hospitalized >2 times for 
MRSA bacteremia. Chart abstraction was performed 
by 2 independent reviewers with no access (blinded) to 
laboratory data. Each reviewer separately examined 10% of 
charts; the κ statistic for coding of exemplar key variables 
was 0.87, indicating excellent agreement (18). Each new 
hospital admission was categorized as a new episode of 
bacteremia; the ﬁ  rst positive blood culture was used as 
the index infection. We abstracted patient information 
regarding demographics, concurrent illnesses, patient’s 
residence before hospitalization (facility vs. community), 
bacteremia severity, and previous health care exposures.
Deﬁ  nitions
We categorized each MRSA infection into 1 of 3 
groups according to Etest result for vancomycin MICs as 
follows: VISA (MIC 4–12 μg/mL), hVISA, or non–VISA/
hVISA MRSA (MIC <2 μg/mL). We also assessed MIC50 
and MIC90 for vancomycin.
We deﬁ   ned the number of days to clearance of 
bacteremia as the date of ﬁ   rst positive MRSA culture 
subtracted from the date of ﬁ  rst negative culture for all 
patients for whom this information was available. Episodes 
of bacteremia ended on the date of death or on the date 
of the ﬁ  rst negative blood culture that was not followed 
by a positive culture within 7 days. We did not study 
subsequent episodes during the same hospitalization. 
Vancomycin trough levels were measured after 3 doses of 
vancomycin; if multiple levels were measured, the modal 
level was used and classiﬁ  ed as either >15 μg/mL or <15 
μg/mL. We deﬁ  ned prior vancomycin exposure as receipt 
of >3 doses of vancomycin at least 7 days and <12 months 
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before MRSA bacteremia. Empirically prescribed therapy 
was deﬁ   ned as appropriate if MRSA were susceptible 
to the antimicrobial drug used (according to in vitro 
susceptibility testing) and if therapy was started within 
48 hours of the blood culture result. History of MRSA 
infection was deﬁ  ned as hospitalization with MRSA during 
the prior 12 months. We deﬁ  ned an episode as community 
associated if the patient was bacteremic within 48 hours 
of hospitalization and lacked health care–associated risk 
factors such as dialysis, nursing home residence, or history 
of MRSA infection. We divided health care–associated 
MRSA cases into community onset or hospital onset. Cases 
were health care–associated community onset if the patient 
had such risk factors and was found to be bacteremic within 
48 hours of hospital admission; cases were of health care–
associated hospital onset if the bacteremia occurred after 
48 hours of hospitalization, consistent with the schema of 
Klevens et al. (19).
We deﬁ   ned renal insufﬁ   ciency as serum creatinine 
level >2 mg/dL or glomerular ﬁ   ltration rate <50 mL/
min/1.73 m2 according to the Cockcroft-Gault equation. The 
source of the bacteremia was determined by a combination 
of positive MRSA culture growth from a site other than 
blood, radiologic evidence, or an attending physician’s 
statement in the medical record. We used the Duke criteria 
to deﬁ   ne endocarditis (20). Severity of bacteremia at 
onset of infection was determined by use of vasopressors, 
elevation of serum creatinine levels from baseline (renal 
insufﬁ   ciency), and admission to an intensive care unit 
after positive MRSA blood culture result. The major 
patient outcome measure was 90-day all-cause mortality 
rate. Mortality rate was determined by calculating deaths 
from the date of positive MRSA blood culture result up 
to 90 days while hospitalized, divided by the number of 
patients in the study (n = 603). Data regarding death after 
hospital discharge were not available for analysis. MRSA-
attributable deaths were not included because of the 
difﬁ  culty in assessing exact cause of death. 
Statistical Analysis
We used SAS version 9.1 (SAS Institute, Cary, NC, 
USA) for statistical analyses (21). We used standard 
methods to describe univariate data and to calculate 
t-tests, and we used χ2 for bivariate associations. We used 
generalized linear models (SAS Proc GLM) to assess 
associations between the 3 groups of MRSA infection 
and quantitative variables. We conducted multivariable 
analyses by using logistic regression (SAS Proc Logistic). 
We developed models for 3 variables: infection with 
VISA, infection with hVISA, and death. Model building 
was guided ﬁ  rst by conceptual models of likely effect and 
informed by our bivariate analysis results. We assessed 
correlation coefﬁ  cients between pairs of potential predictor 
variables by using appropriate parametric or nonparametric 
methods and included only 1 of any pair of variables with 
an r2 of >0.25 in any model. Guided by the rule for stability 
of estimates established by Peduzzi et al., we limited the 
total number of predictor variables in any model (22). The 
signiﬁ  cance of the models (Tables 1, 2) are demonstrated by 
likelihood ratios, Wald <0.0001. When choosing between 
similar or comparable models, we selected the model 
associated with the smallest Akaike information criterion 
(<582); for example, in our analysis of predictors of risk for 
death, we rejected variables indicating HIV, malignancy, 
transplant, recent surgery, and presence of a medical device 
because they increased the Akaike information criterion. 
The predictive and discriminative performance of our 
models is shown in Tables 1 and 2. Our model predicting 
death has a c-score of 0.872; among 99,198 pairs, 87.1% 
were concordant, 12.7% were discordant, and 0.2% had the 
same scores. Although we also present the more familiar 
adjusted odds ratios, our primary measures of impact are 
adjusted risk measures (adjusted risk ratio and adjusted 
risk difference), which we derived from regression risk 




Each year during 2002–2006, the annual number of 
hospital admissions in this study were 117, 77, 147, 121, 
and 161, respectively; through May 31, 2007, another 
76 patients were hospitalized (equivalent to 184 annual 
hospitalizations). The original testing of strains by 
Microscan did not detect VISA; repeat testing using the 
Vitek 2 detected 2 (25%) of 8 study strains and 2 (20%) 
of 10 control strains. The rate at which polymicrobial 
bacteremia met inclusion criteria was 3% (20 episodes). 
The Figure demonstrates the proportion of VISA, hVISA, 
and non–VISA/hVISA MRSA by year and the increase 
in mean vancomycin MICs during the study period. The 
vancomycin MICs for most (87%) isolates were 1–2 μg/
mL. For VISA, MICs were as high as 12 μg/mL, although 
for 60%, MICs were 4 μg/mL. For 94% of hVISA strains, 
vancomycin MICs were 1.5–2.0 μg/mL.
The geometric mean MIC of vancomycin was 1.7 
μg/mL; modal MIC = 2 μg/mL. In 2002, the MIC50 of 
vancomycin was 1.5 μg/mL; by 2007, it was 2 μg/mL. The 
MIC90 was constant during the study period; vancomycin 
MIC90 was 4 μg/mL in 2002 and 2004–2007.
Patient Characteristics
Key patient characteristics are shown in Table 3. Recent 
medical care seemed to be associated with type of strain. 
Nearly 40% of infections were health care–community 
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associated, almost all the rest were hospital associated. 
Average length of stay for patients with all infection types 
was 32.9 days. Many cases of MRSA bacteremia were 
in patients with renal insufﬁ  ciency and/or cardiovascular 
disease; >40% had recently had a surgical procedure. 
Many (43%) cases of bacteremia were secondary to central 
venous catheter infections. The 90-day all-cause mortality 
rate was 31.5% for the 603 patients; rate was 27.2% when 
all 699 episodes of bacteremia were considered.
Treatment and Changes in Treatment Regimens
Among the 603 patients, 47% had been exposed 
to vancomycin and 60% of these had had prior MRSA 
infection. Prior vancomycin exposure was more likely for 
patients with VISA (62%, 95% CI 47.7%–65.3%) than for 
patients with hVISA (42%, 95% CI 29.4%–59%) or other 
MRSA strains (47%, 95% CI 41.3%–49.7%).
Among the 699 episodes of MRSA bacteremia, 
vancomycin was used to treat 566 (81%) episodes. Initial 
vancomycin treatment was switched to daptomycin or 
linezolid for 12% of MRSA (non-VISA, non-hVISA) 
infections and 15% of VISA infections. For the 699 episodes 
of bacteremia, mortality rates were 27.2% overall, 16% 
(95% CI 6.8%–24.8%) when antimicrobial drug treatment 
was changed, and 26% (95% CI 22.2%–29.8%) when not 
changed. Our data did not enable us to determine the extent 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 7, July 2012  1075
Table 1. Multivariable analysis of risk factors for VISA and hVISA infections, New York, New York, USA, 2002–2007* 
Risk factor and MRSA strain  Odds ratio  Adjusted risk ratio (95% CI)  Adjusted risk difference (95% CI)† 
Age‡      
  VISA  0.93  0.82 (0.65 to 1.12)  –0.020 (–0.080 to 0.007) 
  hVISA  0.93  0.96 (0.73 to 1.35)  –0.003 (0.050 to 0.013) 
Race/ethnicity      
 Black       
    VISA  0.90  0.76 (0.35 to 1.57)  –0.02 (–0.07 to 0.04) 
  hVISA  0.90  1.03  (0.44  to  2.13)  0.002 (0.050 to 0.070) 
 Hispanic       
    VISA  0.89  0.87 (0.36 to 1.88)  –0.01 (–0.06 to 0.05) 
  hVISA  0.46  0.62  (0.19  to  1.37)  0.03 (0.08 to 0.03) 
 Asian       
  VISA  1.97  1.79 (0.77 to 3.34)  0.06 (0.02 to 0.15) 
  hVISA  1.58  1.65 (0.66 to 3.21)  0.05 (0.03 to 0.14) 
Concurrent condition       
 Diabetes       
  VISA  1.42  1.44  (0.78  to  2.59)  0.03 (0.02 to 0.08) 
  hVISA  0.69  0.87  (0.48  to  1.48)  0.01 (0.05 to 0.03) 
 Chronic  hemodialysis       
  VISA  1.25  1.23  (0.56  to  2.57)  0.02 (0.04 to 0.09) 
  hVISA  1.32  1.05  (0.48  to  2.03)  0.004 (0.040 to 0.060) 
 HIV       
  VISA  0.50  0.45  (0.09  to  1.06)  –0.05 (0.090 to 0.004) 
  hVISA  0.30  0.27  (0.06  to  1.38)  0.060 (0.100 to 0.008) 
 Liver  cirrhosis       
    VISA  2.38  3.43 (2.02 to 6.00)  0.14 (0.06 to 0.23) 
    hVISA  2.55  2.11 (1.06 to 3.87)  0.080 (0.005 to 0.170) 
 Malignancy       
    VISA  2.02  1.96 (1.07 to 3.31)  0.070 (0.005 to 0.130) 
  hVISA  1.37  1.64  (0.87  to  3.07)  0.04 0.01 to 0.11) 
Other        
  Nursing home residence       
    VISA  1.62  1.83 (0.88 to 3.30)  0.060 (–0.009 to 0.130) 
    hVISA  1.12  0.94 (0.36 to 1.80)  –0.005 (–0.060 to 0.050) 
 Surgical  procedure§       
    VISA  0.50  0.41 (0.20 to 0.76)  –0.06 (–0.10 to –0.02) 
    hVISA  0.79  0.62 (0.32 to 1.02)  –0.040 (–0.080 to 0.002) 
  Prior receipt of vancomycin       
    VISA  1.87  2.09 (1.25 to 3.67)  0.06 (0.02 to 0.10) 
  hVISA  0.92  0.97  (0.56  to1.65)  0.002 (0.040 to 0.040) 
  Central venous catheter infection       
    VISA  0.80  0.83 (0.50 to1.36)  –0.01 (–0.05 to 0.02) 
    hVISA  2.09  1.81 (1.13 to 3.10)  0.050 (0.009 to 0.090) 
*Results from logistic regression with outcomes and covariates. VISA, vancomycin-intermediate Staphylococcus aureus strains, hVISA, heteroresistant 
vancomycin-intermediate S. aureus strains; MRSA, methicillin-resistant S. aureus.
†Adjusted risk difference refers to the absolute difference in risk; for example, an adjusted risk difference of 0.10 signifies a 10% increased risk for hVISA, 
VISA, given that variable. 
‡Measures are adjusted odds ratio for a 10-y difference and adjusted risk difference for effect of age 50–60 y. 
§Surgical procedures under general anesthesia within the past 3 months. RESEARCH
to which switching, or not switching, antimicrobial drugs 
contributed to survival. 
Correlates of VISA and hVISA Infections
Multivariable analyses (Table 1) demonstrate 
associations between key clinical characteristics and 
VISA or hVISA infections. The adjusted risk difference 
represents the absolute difference in risk for that given 
characteristic, all else held equal. Cirrhosis of the liver 
and central venous catheter infections nearly doubled the 
risk for hVISA infection. Cirrhosis and active malignancy 
increased the absolute risk for VISA by 14% and 7%, 
respectively. History of vancomycin exposure within 1 
year increased the risk for VISA (6%) but did not increase 
the risk for hVISA infection.
Predictors of All-Cause Death
The effect of various clinical characteristics on risk 
for death within 90 days is summarized in Table 2. For 
patients with concomitant MRSA bacteremia, older age 
increased the risk of dying. Cirrhosis or renal insufﬁ  ciency 
and having lived in a nursing home before hospitalization 
or having been admitted to an intensive care unit were each 
independently associated with death (after adjusting for 
covariates in the model); each increased the risk of dying 
by 7%–15%. Patients who required vasopressors had an 
absolute increase in risk for death of ≈50%, after covariates 
were adjusted for. Risk for death was independently 
associated with lower risk for death among those who had 
diabetes mellitus or who had had a vascular graft as the 
source of the infection. A consultation with an infectious 
diseases specialist decreased the risk for death by 11%. 
Neither a VISA nor hVISA strain was independently 
associated with all-cause death after covariates in the 
models were controlled for.
A subanalysis of vancomycin MICs for strains 
infecting patients who died in the hospital found that the 
mean MIC was 1.7 μg/mL. The current breakpoint of 
vancomycin susceptibility is 2 μg/mL.
Discussion
The idealized model for the treatment of patients with 
infectious diseases incorporates the triad of host, organism, 
and drug. Organisms and drugs are more easily classiﬁ  ed 
and hence more accessible for systematic study. Our study 
of the 5-year experience with MRSA infections in adults at 
a major New York City medical center illustrates why such 
a dyadic approach might be insufﬁ  cient. For example, the 
MIC, which characterizes the major intersection between 
organism and drug, was overshadowed by a constellation of 
clinical factors when predicting risk for death. Vancomycin 
MICs from isolates from most persons who died indicated 
nominal susceptibility. Several other studies have shown 
vancomycin MIC to not be a predictor of death (10,12,13).
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Table 2. Multivariable analysis of risk factors for 90-day all-cause deaths among 603 patients with MRSA bacteremia, New York, New 
York, USA, 2002–2007* 
Risk factor  Odds ratio (95% CI)  Adjusted risk ratio (95% CI)  Adjusted risk difference† (95% CI)
Age‡  1.72 (1.29 to 2.30)  1.34 (1.12 to 1.65)  0.04 (0.03 to 0.05) 
Race/ethnicity      
  Black  0.71 (0.39 to 1.29)  0.85 (0.63 to 1.16)  –0.04 (–0.04 to –0.11) 
  Hispanic  0.85 (0.45 to 1.58)  0.93 (0.66 to 1.23)  –0.02 (–0.10 to 0.06) 
  Asian  1.83 (0.92 to 3.66)  1.30 (0.95 to 1.72)  0.08 (–0.01 to 0.18) 
Concurrent condition       
  Diabetes  0.50 (0.31 to 0.83)  0.73 (0.57 to 0.93)  –0.08 (–0.14 to –0.02) 
  Immunosuppressant use  0.83 (0.37 to 1.83)  0.92 (0.63 to 1.30)  –0.02 (–0.10 to 0.08) 
  Liver cirrhosis  2.18 (1.16 to 4.12)  1.40 (1.04 to 1.77)  0.10 (0.01 to 0.19) 
  Renal insufficiency  1.89 (1.18 to 3.01)  1.33 (1.05 to 1.70)  0.08 (0.01 to 0.14) 
Other      
  Infectious disease consultation  0.43 (0.26 to 0.69)  0.69 (0.57 to 0.86)  –0.11 (–0.16 to –0.04) 
  History of MRSA infection   0.77 (0.45 to 1.34)  0.89 (0.70 to 1.13)  –0.03 (–0.09 to 0.04) 
  Nursing home residence  3.08 (1.81 to 5.24)  1.62 (1.31 to 2.06)  0.15 (0.08 to 0.23) 
  Intensive care unit stay  1.71 (1.17 to 2.50)  1.29 (1.11 to 2.15)  0.07 (0.03 to 0.20) 
  Vasopressor use  15.44 (8.58 to 27.76)  3.67 (2.66 to 4.66)  0.48 (0.34 to 0.58) 
  Inappropriate antimicrobial drug therapy  1.38 (0.73 to 2.63)  1.15 (0.89 to 1.46)  0.04 (–0.03 to 0.12) 
MRSA strain       
  VISA  0.58 (0.24 to 1.38)  0.78 (0.49 to 1.19)  –0.06 (–0.15 to 0.05) 
  hVISA  1.23 (0.54 to 2.82)  1.10 (0.67 to 1.58)  0.03 (–0.09 to 0.16) 
Infection source       
  Pneumonia  1.77 (0.85 to 3.64)  1.28 (0.91 to 1.68)  0.07 (–0.02 to 0.17) 
  Vascular graft infection  0.21 (0.03 to 1.70)  0.460 (0.005 to 0.940)  –0.15 (–0.29 to –0.02) 
  Endocarditis  1.49 (0.80 to 2.79)  1.19 (0.87 to 1.51)  0.05 (–0.03 to 0.13) 
*Results from logistic regression with outcomes and covariates. MRSA, methicillin-resistant Staphylococcus aureus.
 VISA, vancomycin-intermediate S. aureus strains, hVISA, heteroresistant vancomycin-intermediate S. aureus strains. 
†Adjusted risk difference refers to the absolute difference in risk; for example, an adjusted risk difference of 0.10 signifies a 10% increased risk for all-
cause deaths given that variable. 
‡Measures are adjusted odds ratio for a 10-y difference and adjusted risk difference for effect of age 50–60 y. Risk for Death from MRSA Bacteremia
Unlike others, who considered concurrent conditions 
by using scales such as the Charlson Index (15,24), we 
investigated the association between speciﬁ  c  patient 
characteristics, organisms, drugs, and outcomes. Not all 
concurrent conditions were alike in either magnitude or 
direction of effect. Regression risk analysis enabled us 
to identify the independent contribution of these factors 
in relative and absolute terms. We identiﬁ  ed  critical 
prognostic factors, including concurrent conditions 
(cirrhosis and renal insufﬁ   ciency suggested a poorer 
prognosis; diabetes, a better one) and source of admission 
(nursing home residence suggested a poorer prognosis). 
We learned that strain type was not an independent 
negative prognostic factor. As one might expect, the use of 
vasopressors presaged an increased risk for death (adjusted 
risk difference = 48%).
Our ﬁ  ndings can help clinicians estimate the risk that 
a patient with MRSA bacteremia will die. For example, an 
elderly patient with liver cirrhosis and MRSA bacteremia 
who lived in a nursing home before hospital admission 
would have an extremely poor prognosis. Conversely, an 
otherwise healthy patient with diabetes mellitus might have 
a better prognosis that could be improved even more by 
consultation with an infectious disease specialist. We note 
paradoxically that several of the positive predictive factors 
(such as diabetes and vascular graft infections) represent 
situations in which host barriers to infections might be 
impaired. We speculate that host, organism, and drug 
factors might all interact; an impaired host might become 
infected by a less aggressive organism that in turn is more 
susceptible to drugs. In this study, ≈30% of patients with 
skin and soft tissue infections had diabetes mellitus with 
varying levels of baseline glucose control. Thus, the source 
of infection and spectrum of disease might also affect risk 
for death. This and alternate hypotheses should be explored 
in future research.
There is controversy regarding the value of testing for 
hVISA (25). Although this article is unlikely to resolve 
that controversy, we can say that patients infected with 
these strains in our cohort probably did not have increased 
risk for death from all causes. Other reports suggest that 
a down-regulation of virulence might be associated with 
increased vancomycin resistance (12,26).
We observed trends in which vancomycin MICs crept 
upward over the 5 years of the study. As a corollary, the 
likelihood of VISA infections increased. The rate of hVISA 
infections during 2002–2007 was steady, around 8%, similar 
to that described in the literature (27,28). Prior exposure 
to vancomycin was a contributing factor for infection with 
VISA strains (29–31). Although we describe a vancomycin 
MIC creep, the MIC90 of vancomycin remained relatively 
stable over the 5-year period, perhaps hinting at why MIC 
did not independently predict death.
A recent study by Paul et al. found a signiﬁ  cant increase 
in 30-day mortality rates for patients given incorrect 
therapy within 48 hours of blood culture (32). Schweizer et 
al. did not ﬁ  nd an increase in hospital deaths among similar 
patients with S. aureus bacteremia (33). Our study was 
limited by our inability to assess deaths that occurred out 
of the hospital.
Consistent with mortality rates reported in the 
literature, ≈32% of our patients died (34). Considering the 
marginal impact of several independent risk factors, our 
innovative presentation of adjusted risk differences offers 
clinicians a quantiﬁ  able way to assess their patients’ risk 
for death. Although the numbers were too low to analyze 
with multivariable models, we note the trend toward 
improved prognosis among those for whom antimicrobial 
drug therapy was switched and recognize that because 
switches are likely for patients who are not doing well 
clinically, that the most apparent bias is against such 
a ﬁ  nding. Thus, our ﬁ  ndings hint at potential beneﬁ  t for 
prescribing alternative drugs if patients are not improving. 
Two recent studies have shown that consultations with an 
infectious diseases specialist lower the risk for death from 
S. aureus bacteremia (35,36).
This study is limited by its retrospective design and 
single-center setting. MICs derived by using Etest might 
be higher than those derived by microdilution (37). 
hVISA strains were identiﬁ   ed by using a method with 
demonstrably high sensitivity and speciﬁ  city and not by 
using the standard method (10,38,39). We did not test for 
hVISA on the 5% of isolates for which vancomycin MIC 
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Figure. Trend of methicillin-resistant Staphylococcus aureus 
(MRSA) infection strain types, New York, New York, USA, 2002–
2007. VISA, vancomycin-intermediate S. aureus strains, hVISA, 
heteroresistant vancomycin-intermediate S. aureus strains.RESEARCH
was <1 μg/mL; other studies have noted few or no hVISA 
in this MIC group (10,24,25,27). The accuracy of timing 
of vancomycin trough levels was limited. Daily bacterial 
cultures were not always conducted, decreasing the data 
points for clearance of bacteremia. Misclassiﬁ  cation error 
is possible because we reviewed records available at Mount 
Sinai Medical Center only. Almost all study patients had 
sufﬁ  cient contact with the health care system that not many 
infections were classiﬁ  ed as community acquired, limiting 
our ability to generalize to those infections. As noted, we 
were limited by our inability to link to death data outside of 
the hospital records.
Until now, the major focus on active MRSA infections 
has been on the organism and its susceptibility to the drug. 
Although decreased vancomycin susceptibility has resulted 
in prolonged bacteremia and treatment failure in several 
studies (15,24), our ﬁ  ndings suggest that incorporating the 
context, the host, and the environment is similarly useful. 
Our study emphasizes that after a diagnosis of MRSA 
bacteremia is made, it is crucial to determine patient risk 
factors and not just the vancomycin MIC for the infecting 
strain. The consequences of MRSA bacteremia are clear—
many patients will die or experience a decline from their 
baseline clinical condition. The adjusted risk difference 
enables clinicians to use a targeted approach, directed 
toward patients with the highest risk for death—i.e., the 
elderly, patients with liver cirrhosis, patients with renal 
insufﬁ   ciency, and patients from nursing homes. These 
patients should be treated carefully and should possibly 
receive a consult from an infectious diseases specialist. 
What remains unclear is whether patients with increased 
risk for death should be treated with antimicrobial drugs 
other than vancomycin. 
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Table 3. Clinical characteristics for patients with MRSA bacteremia by strain type, New York, New York, USA, 2002–2007* 
Characteristic  VISA, n = 55  hVISA, n = 55 
non–VISA/hVISA
MRSA, n = 589  p value 
Age, mean y ± SD†  58.7 ± 16.5  58.7 ± 16.5  63 ± 17.3  0.04 
Length of stay, mean d ± SD  33.7 ± 41.4  30.9 ± 22.7  34 ± 41.9  0.49 
Days to negative culture, mean ± SD  3.7 ± 2.8  3.6 ± 3.2  4.3 ± 4.8  0.98 
Male sex  29 (52.7)  28 (50.9)  340 (57.7)  0.51 
Race/ethnicity       
  White  19 (34.5)  21 (38.2)  238 (40.4)  0.59 
  Black  15 (27.3)  14 (25.5)  160 (27.2)  0.96 
  Hispanic  12 (21.8)  7 (12.7)  123 (20.9)  0.34 
  Asian  9 (16.4)  10 (18.2)  65 (11.0)  0.17 
General       
  Hospitalization within 1 mo of MRSA infection  29 (52.7)  17 (30.9)  295 (50.1)  0.02 
  Prior MRSA infection   22 (40.0)  7 (12.7)  159 (27.0)  0.006 
  Prior vancomycin exposure  34 (61.8)  25 (45.5)  272 (46.2)  0.08 
  Vancomycin trough >15 μg/mL  34 (61.8)  25 (45.5)  387 (65.7)  0.0005 
  Inappropriate antimicrobial drug therapy  12 (21.8)  4 (7.3)  66 (11.2)  0.09 
  Infectious diseases consultation  34 (61.8)  23 (41.8)  404 (68.6)  0.0003 
  Health care–associated hospital infection  19 (34.5)  28 (50.9)  340 (57.7)  0.003 
  Health care–associated community infection  31 (56.4)  25 (45.5)  241 (40.9)  0.08 
Concurrent  conditions       
  Renal insufficiency  35 (63.6)  29 (52.7)  309 (52.5)  0.48 
  Chronic hemodialysis  19 (34.5)  12 (21.8)  128 (21.7)  0.09 
  Diabetes mellitus  27 (49.1)  18 (32.7)  209 (35.5)  0.11 
  HIV  5 (9.1)  2 (3.6)  60 (10.2)  0.29 
  Cardiovascular disease  33 (60.0)  31 (56.4)  399 (67.7)  0.14 
  Malignancy  14 (25.5)  17 (30.9)  117 (19.9)  0.11 
  Transplant  7 (12.7)  11 (20.0)  46 (7.8)  0.007 
  Cirrhosis  22 (40.0)  14 (25.5)  78 (13.2)  <0.0001 
  Steroids  17 (30.9)  12 (21.8)  193 (32.8)  0.25 
  Surgery <3 mo before MRSA infection  14 (25.5)  19 (34.5)  271 (46.0)  0.005 
  Implanted device  8 (14.5)  7 (12.7)  151 (25.6)  0.02 
  Intensive care unit stay  23 (41.8)  26 (47.3)  273 (46.3)  0.96 
Infection  source       
  Central venous catheter  27 (49.1)  33 (60.0)  242 (41.1)  0.04 
  Pneumonia  10 (18.2)  6 (10.9)  39 (6.6)  0.62 
  Endocarditis  7 (12.7)  3 (5.5)  81 (13.8)  0.22 
  Wound/skin or soft tissue  10 (18.2)  10 (18.2)  92 (15.6)  0.80 
  Bone/joint  6 (10.9)  1 (1.8)  65 (11.0)  0.10 
  Vascular graft  2 (3.6)  1 (1.8)  17 (2.9)  0.85 
Death within 90 d of MRSA infection  15 (27.3)  14 (25.5)  161 (27.3)  0.38 
*Values are no. (%) with a given variable per strain type unless otherwise indicated. MRSA, methicillin-resistant Staphylococcus aureus; VISA, 
vancomycin-intermediate S. aureus strains, hVISA, heteroresistant vancomycin-intermediate S. aureus strains.  
†N = 699. Risk for Death from MRSA Bacteremia
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